📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-25 13:31
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
27 announcements match the current filters (relevance ≥ 5).
IOLCP Receives EDQM Approval for Fenofibrate Process II Effective Sept 24, 2026
IOL Chemicals and Pharmaceuticals Limited announced that the European Directorate for the Quality of Medicines & HealthCare (EDQM) granted a Certificate of Suitability (CEP) for 'FENOFIBRATE – Process II' on September 24, 2026. This approval comes in addition to an existing valid CEP already held for Fenofibrate. Process II was developed to meet specific customer requirements in regulated markets, supporting the company's export diversification strategy beyond Ibuprofen and Ethyl Acetate (which comprised 72% of FY24 sales). While no financial terms or capacity additions were quantified, the approval bolsters IOLCP's portfolio of 18+ approved CEPs targeting European and US markets.
Confidence: HIGH
What changedIOLCP secured an additional Certificate of Suitability from EDQM for Fenofibrate - Process II, valid from September 24, 2026.
Why it mattersEnables the company to supply Fenofibrate manufactured under Process II directly into regulated European markets, advancing its goal to reduce concentration risk and raise export share.
Approval Date: 24 September 2026Existing CEP count across portfolio: 18TTM Revenue Context: Rs 2523 Cr
📅 Short termPositive regulatory development indicating execution on expanding the non-Ibuprofen API pipeline, though revenue impact will take quarters to reflect.
📈 Long termSupports the company's stated strategy to broaden its regulated market presence (Europe/US) and diversify its API portfolio away from heavy reliance on Ibuprofen.
⚠ Risk flags
- Commercialization timeline and order volumes from European customers are not disclosed
- High dependency on China for chemical raw materials poses margin volatility risk
Key Highlights
Received Certificate of Suitability (CEP) from EDQM on 24th September 2026
Approval granted for API product 'FENOFIBRATE – Process II'
Complements existing valid CEP already held by IOLCP for Fenofibrate
Process II specifically developed to address customized client manufacturing requirements in regulated markets
👀 What to Watch
Track export revenue contribution and commentary in upcoming quarterly results regarding the commercial rollout and client uptake of Fenofibrate Process II.
IOL Chemicals Secures EU-REACH Registration for Triacetin to Expand European Exports
IOL Chemicals and Pharmaceuticals Limited announced that it has received REACH certification and registration for its product Triacetin under the EU-REACH framework from the European Chemicals Agency (ECHA). This regulatory approval permits the company to export Triacetin across all European Union member states. The approval aligns with IOLCP's broader strategy to expand in regulated export markets to achieve higher-margin sales. Financial contribution details and target volumes for Triacetin were not disclosed in the filing.
Confidence: HIGH
What changedIOL Chemicals has formally obtained EU-REACH registration for Triacetin, removing regulatory barriers to sell the chemical across the European Union.
Why it mattersEnables geographic expansion into regulated European markets, supporting the company's strategic push to diversify revenue beyond core products like Ibuprofen and Ethyl Acetate.
Product registered: TriacetinRegulatory authority: European Chemicals Agency (ECHA)Announcement date: 23rd September 2026Financial value / targets: not disclosed
📅 Short termLimited direct financial impact immediately, but positive for regulatory validation and sentiment regarding product portfolio diversification.
📈 Long termSupports the management strategy to shift revenue mix toward regulated export markets and higher-value specialty chemicals and APIs over upcoming quarters.
⚠ Risk flags
- Commercial uptake and pricing in the competitive European chemical market remain unquantified
- Product concentration risks still persist in the medium term
Key Highlights
Received REACH certification/registration for product 'Triacetin' under the EU-REACH framework
Approval granted by the European Chemicals Agency (ECHA) announced on 23rd September 2026
Enables export of Triacetin across all European Union member countries
Specific financial contribution, capacity allocation, or sales targets were not disclosed
👀 What to Watch
Track subsequent quarterly commentary to assess commercial export volumes of Triacetin to Europe and its contribution to IOLCP's non-Ibuprofen chemical sales.
IOLCP Details ₹500 Cr Capex Plan to Boost Ibuprofen Capacity and Enter CDMO Formulations
IOL Chemicals and Pharmaceuticals Limited (IOLCP) conducted an investor call detailing three growth initiatives requiring ~₹500 crore in capex (~20% of TTM revenue). The plan includes expanding Ibuprofen API capacity by 6,000 MTPA to 18,000 MTPA by December 2027 and setting up an EU GMP-certified CDMO formulation facility with a 1,500 million tablets/year capacity starting commercialization in Q3 FY27. Management also disclosed a dedicated tolling facility for specialty chemicals under a long-term customer agreement. Combined, these initiatives are expected to generate an incremental 25% to 30% top-line growth and will be funded entirely through internal accruals, with ~30% already incurred.
Confidence: HIGH
What changedIOLCP outlined operational and financial details for three strategic capex projects totaling ~₹500 crore at its existing site.
Why it mattersThe capex strengthens IOLCP's global leadership in Ibuprofen while diversifying revenue into CDMO formulations and dedicated tolling specialty chemicals, expanding operating margins via backward integration.
Total capex: ₹500 croreCapex vs TTM revenue: ~19.8%Capex vs Net worth: ~27.8%Ibuprofen capacity addition: 6,000 MTPANew total Ibuprofen capacity: 18,000 MTPACDMO facility capacity: 1,500 million tablets per annum
📅 Short termPositive sentiment driven by management's confirmation of internal-accrual funding and commercialization timelines, with the CDMO unit starting operations in Q3 FY27.
📈 Long termSubstantial growth pipeline providing 25-30% revenue expansion and product diversification away from high reliance on basic bulk API chemicals.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution timeline delays given Ibuprofen commissioning is slated for late 2027
- Customer adoption and regulatory sign-offs for the new CDMO formulation business
Key Highlights
Proposed total capex of ~₹500 crore funded entirely via internal accruals, with ~30% already incurred
Expanding Ibuprofen capacity by 6,000 MTPA to 18,000 MTPA, scheduled for commissioning by December 2027
New CDMO facility with capacity of ~1,500 million tablets per annum (EU GMP certified), starting Q3 FY27
Projects expected to contribute an incremental 25% to 30% to total top-line over coming years
Capex projects target asset turns of 1.75x to 2.0x for pharma API investments
👀 What to Watch
Track the commercialization ramp-up of the CDMO formulation plant starting Q3 FY27 and monitor ongoing milestone spending towards the December 2027 Ibuprofen commissioning.
IOLCP Announces ₹495 Cr Capex: 50% Ibuprofen Expansion, CDMO & Specialty Chemical Units
IOL Chemicals has announced three strategic manufacturing initiatives with an aggregate capex of ₹495 crore, all funded via internal accruals (~27.5% of net worth). First, it is expanding its Ibuprofen capacity by 50% from 12,000 MTPA to 18,000 MTPA at a cost of ₹350 crore, slated for commissioning by December 2027. Second, it has set up a ₹110 crore formulations CDMO unit (1,500 million tablets/year) targeting Europe, which has received EU GMP approval from Hungary and is expected to commercialize in Q3 FY27. Third, it is investing ₹35 crore for a dedicated specialty chemicals tolling facility for a leading global chemical company, also targeted for Q3 FY27.
Confidence: HIGH
What changedIOLCP committed to a ₹495 crore aggregate capex program covering an API capacity hike, European CDMO entry, and dedicated specialty chemical tolling.
Why it mattersThe capex represents ~19.6% of TTM revenue (₹2,523 Cr) and ~27.5% of net worth (₹1,799 Cr), significantly expanding its global Ibuprofen dominance while diversifying into higher-margin CDMO formulations.
Total announced capex: ₹495 CrTotal capex vs TTM revenue: ~19.6%Ibuprofen capacity addition: 6,000 MTPACDMO formulations capacity: 1,500 million tablets per annumExisting Ibuprofen utilization: 95%
📅 Short termPositive sentiment driver as current Ibuprofen utilization is near peak (95%) and the Hungary GMP approval opens higher-margin European CDMO formulation avenues.
📈 Long termStrengthens global market leadership in Ibuprofen while diversifying revenue away from bulk chemicals and APIs into value-added formulations and long-term specialty chemical tolling.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Project execution and regulatory validation delays across three distinct facilities
- Product concentration in Ibuprofen increases in absolute capacity terms
- Cash flow strain if internal accruals reduce working capital headroom
Key Highlights
Ibuprofen capacity being expanded by 6,000 MTPA (50% increase) to 18,000 MTPA with ₹350 crore capex by Dec 2027
Current Ibuprofen capacity utilization stands at 95% on existing 12,000 MTPA base
New ₹110 crore formulations CDMO unit with 1,500 million tablets/year capacity received Hungary GMP compliance, commercializing in Q3 FY27
Dedicated specialty chemicals tolling facility with ₹35 crore capex signed with a leading global firm, commercializing in Q3 FY27
Total capital expenditure across all three projects is ₹495 crore, funded entirely via internal accruals
👀 What to Watch
Track commercialization progress of the formulations CDMO unit and specialty chemical plant in Q3 FY27, followed by the Ibuprofen unit execution by December 2027.
IOLCP Q1 FY27 Earnings Call: PAT Jumps 89.9% YoY to ₹64.5 Cr; FY27 Growth Guided at 15-20%
IOL Chemicals and Pharmaceuticals reported a 37% YoY growth in Q1 FY27 revenue to ₹756 crore, driven by strong API diversification and higher capacity utilization. Operating EBITDA rose 60.7% YoY to ₹111 crore with margins expanding to 14.6% (up 220 bps YoY), while net profit surged 89.9% YoY to ₹64.5 crore. Non-Ibuprofen API revenue grew 67% YoY to account for 43% of pharma sales. For FY27, management guided for 15-20% revenue growth with EBITDA margins in the range of 14-15% and an export contribution of 25-30%.
Confidence: HIGH
What changedSubmission of the Q1 FY27 earnings call transcript detailing product diversification, export growth, and FY27 guidance.
Why it mattersDemonstrates rapid expansion in non-Ibuprofen APIs (Metformin, Paracetamol, Clopidogrel), reducing legacy product concentration and improving operating leverage.
Q1 FY27 Revenue: ₹756 crQ1 FY27 PAT: ₹64.5 crEBITDA Margin: 14.6%FY27 Revenue Growth Guidance: 15% to 20%Export Share: 28.5%
📅 Short termStable to positive sentiment following solid Q1 operating execution and steady margin guidance.
📈 Long termPortfolio diversification into non-ibuprofen APIs and regulatory approvals (like China NMPA for Clopidogrel) enhance structural growth resilience and margin profile.
⚠ Risk flags
- Raw material price volatility in basic chemicals and reliance on imported inputs
- Sustained pricing pressure in competitive bulk generic chemical and API segments
Key Highlights
Revenue from operations grew 37% YoY to ₹756 crore in Q1 FY27 compared to ₹551 crore in Q1 FY26
Net profit surged 89.9% YoY to ₹64.5 crore with PAT margin improving to 8.4% vs 6.1% in Q1 FY26
Non-Ibuprofen pharma revenue increased 67% YoY, contributing 43% of pharma sales vs 36% in Q1 FY26
FY27 guidance targets 15-20% revenue growth and 14-15% EBITDA margins with export share of 25-30%
Paracetamol capacity (10,800 MTPA) utilization stood at ~55%, targeted to reach ~70% by end of FY27
👀 What to Watch
Track the ramp-up in Paracetamol utilization toward the 70% target and the sustainability of EBITDA margins within the guided 14-15% range over upcoming quarters.
89.9% PAT Growth in Q1 FY27; IOLCP Guides 15-20% Revenue Growth and Rs 250 Cr Capex
IOLCP reported a strong Q1 FY27 with revenue growing 37.1% YoY to Rs 756.3 Cr and PAT surging 89.9% to Rs 64.5 Cr. The company is successfully diversifying its portfolio, with non-Ibuprofen APIs now contributing 37% of pharma sales compared to 18% in FY21. Management has provided a positive outlook for FY27, guiding for 15-20% revenue growth and EBITDA margins of 14-15%. To support this, a capex of Rs 200-250 Cr is planned, alongside the acquisition of 101 acres for a new manufacturing site.
Confidence: HIGH
What changedIOLCP has transitioned from an Ibuprofen-heavy player to a diversified API manufacturer with significant capacity in Paracetamol (10,800 MTPA) and Ethyl Acetate (1,20,000 MTPA).
Why it mattersThe diversification reduces product concentration risk and improves margin resilience through backward integration and a higher share of value-added APIs in regulated markets.
Q1 FY27 Revenue Growth (YoY): 37.1%Q1 FY27 PAT Growth (YoY): 89.9%FY27 Capex Guidance: Rs 200-250 CrCapex vs Net Worth: ~12.5%New Land Acquisition: 101 acresEBITDA Margin (Q1 FY27): 14.6%
📅 Short termThe stock is likely to react positively to the significant bottom-line growth and the clear 15-20% revenue growth guidance for the full year.
📈 Long termStructural growth is supported by the shift toward regulated markets (US/Europe) and the expansion into a new 101-acre site, which provides a long-term runway for capacity additions.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High dependency on China for chemical raw materials
- Execution risk on new site development
- Product concentration in Ibuprofen and Ethyl Acetate still remains significant
Key Highlights
Q1 FY27 PAT increased by 89.9% YoY to Rs 64.5 Cr, driven by margin expansion.
Revenue from operations grew 37.1% YoY to Rs 756.3 Cr for the quarter.
Non-Ibuprofen API share in the pharmaceutical segment reached 37% in FY26, up from 18% in FY21.
Management guided for a FY27 Capex of Rs 200-250 Cr, representing ~11-14% of current net worth.
Acquired 101 acres of land near Chandigarh-Bathinda Highway for future industrial expansion.
👀 What to Watch
Monitor the execution of the Rs 200-250 Cr capex and the timeline for regulatory approvals for the new 101-acre site. Watch for the company's ability to maintain the 14-15% EBITDA margin guidance amidst volatile raw material costs from China.
89.9% PAT Growth: IOLCP Reports Record ‡756.3 Cr Revenue in Q1 FY27
IOLCP delivered a record-breaking Q1 FY27 with revenue growing 37.1% YoY to ‡756.3 Cr, significantly outpacing its historical quarterly run rate. Net profit (PAT) surged 89.9% YoY to ‡64.5 Cr, driven by a 43% growth in the Pharma segment and a massive 193% jump in Chemical segment EBIT. EBITDA margins expanded to 14.6% from 12.4% YoY, supported by higher capacity utilization and a better product mix. Notably, non-Ibuprofen products now contribute 43% of Pharma revenue, reducing concentration risk.
Confidence: HIGH
What changedIOLCP achieved its highest-ever quarterly revenue and significantly improved its product mix, with non-Ibuprofen APIs now making up nearly half of pharma sales.
Why it mattersThe results demonstrate successful diversification away from Ibuprofen dependence and improved operational leverage, which structurally enhances the company's profitability profile.
Revenue (Q1 FY27): ‡756.3 CrPAT (Q1 FY27): ‡64.5 CrEBITDA Margin: 14.6%Q1 Revenue vs TTM Revenue: 32.6%Paracetamol Utilization: 65%Export Share: 28.5%
📅 Short termThe stock is likely to react positively to the sharp beat in earnings and margin expansion compared to previous quarters.
📈 Long termThe transition toward a diversified API portfolio and increased presence in regulated markets like China and Europe provides a more stable growth trajectory.
⚠ Risk flags
- Raw material price volatility in China
- Geopolitical supply chain disruptions
Key Highlights
Revenue from operations reached a record ‡756.3 Cr, up 37.1% YoY and 22.1% QoQ.
Net Profit (PAT) grew 89.9% YoY to ‡64.5 Cr, accounting for approximately 47% of the total TTM PAT.
Pharma segment revenue grew 43% YoY to ‡469.5 Cr, with EBIT rising 72% YoY.
Paracetamol capacity utilization improved to 65%, meeting the company's previously stated target.
Export contribution increased to 28.5% of total revenue, up from 24.4% in the same quarter last year.
👀 What to Watch
Monitor the sustainability of the 14.6% EBITDA margin and the volume ramp-up in the Chinese market following the recent NMPA approval for Clopidogrel API.
90% PAT Growth: IOLCP Reports Strong Q1 FY27 with ₹756 Cr Revenue
IOLCP reported a robust start to FY27, with consolidated revenue growing 37.1% YoY to ₹756.26 Cr. Net profit surged 89.9% YoY to ₹64.48 Cr, significantly exceeding the quarterly average of the previous year. The growth was primarily driven by the Pharmaceutical segment, which saw a 42.6% YoY revenue increase, while the Chemical segment's profitability (PBIT) nearly tripled to ₹17.32 Cr.
Confidence: HIGH
What changedIOLCP has delivered a significant earnings beat, with quarterly PAT (₹64.48 Cr) representing nearly half of the entire previous year's profit (₹137.48 Cr).
Why it mattersThe results indicate a successful shift toward the higher-margin Pharmaceutical API business and improved operational efficiency in the Chemical segment, reducing the company's historical dependence on low-margin bulk chemicals.
Q1 Revenue vs TTM Revenue: 32.6%Q1 PAT vs TTM PAT: 47.1%Pharmaceutical Segment PBIT Margin: 14.7%Chemical Segment PBIT Margin: 4.7%Cost of Materials as % of Revenue: 67.0%
📅 Short termThe stock is likely to react positively in the short term due to the substantial YoY and QoQ growth in both revenue and profitability.
📈 Long termIf the company continues to scale its 'differentiated API pipeline' (Metformin, Clopidogrel) and increases export share to regulated markets, it could lead to a structural re-rating of the business.
⚠ Risk flags
- High raw material cost concentration (₹506.76 Cr consumed in Q1)
- Product concentration risk in Ibuprofen and Ethyl Acetate
- Dependency on China for chemical raw materials
Key Highlights
Revenue from operations increased 37.1% YoY to ₹756.26 Cr from ₹551.69 Cr.
Net profit for the quarter rose 89.9% YoY to ₹64.48 Cr compared to ₹33.96 Cr in Q1 FY26.
Pharmaceutical segment revenue grew 42.6% YoY to ₹469.49 Cr, now contributing 56% of gross segment revenue.
Chemical segment PBIT improved significantly to ₹17.32 Cr from ₹5.91 Cr in the year-ago period.
Quarterly EPS stood at ₹2.20, which is approximately 47% of the total FY26 EPS of ₹4.69.
👀 What to Watch
Investors should monitor the sustainability of the Pharmaceutical segment's growth and whether the Chemical segment can maintain its improved margins despite raw material volatility. Watch for management commentary on Paracetamol capacity utilization reaching the 65% target.
NMPA China Approves IOLCP's Clopidogrel Bisulfate API on July 14, 2026
IOL Chemicals and Pharmaceuticals (IOLCP) has received regulatory approval from China's NMPA for its Clopidogrel Bisulfate API. This approval allows the company to enter the Chinese pharmaceutical market with this product, complementing its existing European Certificate of Suitability (CEP). This move is part of a broader strategy to diversify its revenue stream, as two products currently account for 72% of total sales. While the immediate financial impact is not disclosed, it supports the company's goal to increase its export revenue share toward 40%.
Confidence: HIGH
What changedIOLCP has gained formal regulatory clearance to market and sell its Clopidogrel Bisulfate API in China, expanding its global footprint.
Why it mattersChina is a massive pharmaceutical market; this approval validates IOLCP's regulatory capabilities and helps diversify its product portfolio away from its heavy reliance on Ibuprofen.
Product Concentration (Top 2): 72%TTM Revenue: Rs 2319 CrExport Revenue Target: 40%Approval Date: 14th July 2026
📅 Short termThe news is likely to be viewed positively by the market as it demonstrates progress in the company's stated strategy of entering regulated markets.
📈 Long termThis is a structural step toward reducing product concentration risk and improving margins by shifting toward higher-value regulated markets like China and Europe.
⚠ Risk flags
- High competition in the Chinese API market
- Raw material price volatility from China
- Execution risk in scaling new product sales
Key Highlights
Approval received from the National Medical Products Administration (NMPA), China, on July 14, 2026.
The approval is for Clopidogrel Bisulfate API, an antiplatelet medication.
IOLCP already holds a valid Certificate of Suitability (CEP) for this product in other markets.
The company is working to reduce its 72% revenue concentration from Ibuprofen and Ethyl Acetate.
👀 What to Watch
Investors should monitor the API segment's revenue growth in upcoming quarters to see how quickly Chinese market access translates into sales volume for Clopidogrel.
IOLCP Reports Strong Q4 FY26: PAT Jumps 68% to ₹53 Cr; Plans ₹1,400 Cr Capex
IOL Chemicals and Pharmaceuticals (IOLCP) delivered a robust performance in Q4 FY26, with revenue growing 17.4% YoY to ₹619 crores and PAT surging 68% to ₹53 crores. The company achieved its highest-ever quarterly revenue, driven by improved capacity utilization in non-Ibuprofen APIs and operational efficiencies. Management has outlined a significant long-term growth plan involving a ₹1,200-1,400 crore capex over the next 4-5 years for a new site, funded entirely via internal accruals. For FY27, the company guides for approximately 15% revenue growth and steady EBITDA margins around 14%.
Key Highlights
Q4 FY26 PAT grew 68% YoY to ₹53 crores, while EBITDA margins expanded by 251 bps to 15.2%
Full-year FY26 revenue reached ₹2,319 crores, up 11.5%, with a total PAT of ₹138 crores
Management announced a mega capex plan of ₹1,200-1,400 crores over 4-5 years for a new 100-acre facility
Capacity utilization for core products like Ibuprofen and Metformin remained high at 85-95%
Non-Ibuprofen segment strengthened with the launch of Minoxidil and expansion of Pantoprazole capacity
👀 What to Watch
Investors should view the margin expansion and diversification into non-Ibuprofen APIs as a positive sign of reduced concentration risk. The massive capex plan indicates long-term growth visibility, though execution and the ability to fund via internal accruals should be monitored.
IOLCP Q4 FY26 PAT Jumps 68.2% YoY to ₹53.2 Cr; EBITDA Margins Expand to 15.2%
IOL Chemicals and Pharmaceuticals (IOLCP) reported a robust Q4 FY26 with revenue growing 17.4% YoY to ₹619.5 Cr and PAT surging 68.2% to ₹53.2 Cr. For the full year FY26, revenue reached ₹2,319.1 Cr with a PAT of ₹137.7 Cr, representing a 36.4% annual growth. The company is successfully diversifying its pharmaceutical mix, with non-Ibuprofen APIs now contributing 37% of segment revenue compared to 18% in FY21. Financial health remains strong with a very low debt-to-equity ratio of 0.08.
Key Highlights
Q4 FY26 EBITDA grew 39.8% YoY to ₹94.3 Cr with margins expanding from 12.7% to 15.2%.
Full-year FY26 revenue from the Pharmaceutical segment rose to ₹1,396.3 Cr from ₹1,212.3 Cr in FY25.
Strategic shift achieved in product mix with non-Ibuprofen APIs now accounting for 37% of pharma sales.
Completed major capacity expansions including Paracetamol (10,800 MTPA) and Ethyl Acetate (1,20,000 MTPA).
Maintained a lean balance sheet with total equity of ₹1,798.4 Cr and a debt-to-equity ratio of 0.08.
👀 What to Watch
Investors should note the significant margin improvement and the successful execution of the diversification strategy which reduces reliance on Ibuprofen. The ramp-up of the new 10,800 MTPA Paracetamol facility and low leverage provide a strong foundation for future growth.
IOLCP Reports Highest-Ever Quarterly Revenue; Q4 PAT Surges 68% YoY to ₹53.2 Cr
IOL Chemicals and Pharmaceuticals achieved its highest-ever quarterly revenue of ₹619.5 crore in Q4 FY26, marking a 17.4% YoY growth. Profitability saw a significant boost with PAT surging 68.2% to ₹53.2 crore and EBITDA margins expanding by 251 bps to 15.2%. The performance was driven by a strong momentum in the non-Ibuprofen pharmaceutical portfolio and improved realizations in the chemicals business. For the full year FY26, the company reported a total revenue of ₹2,319.1 crore and invested ₹164 crore in capacity expansion through internal accruals.
Key Highlights
Q4 FY26 Revenue grew 17.4% YoY to ₹619.5 Cr, the highest quarterly revenue in company history.
EBITDA for the quarter increased 39.8% YoY to ₹94.3 Cr with margins improving to 15.2%.
Net Profit (PAT) for Q4 FY26 surged 68.2% YoY to ₹53.2 Cr compared to ₹31.6 Cr in Q4 FY25.
Pharma segment EBIT rose significantly to ₹62.2 Cr in Q4 FY26 from ₹40.9 Cr in the previous year's quarter.
Annual capex of ₹164 Cr was deployed for capacity expansion in Ethyl Acetate, Acetic Anhydride, and Triacetin.
👀 What to Watch
The significant margin expansion and successful diversification into non-Ibuprofen APIs like Paracetamol and Metformin reduce concentration risk and improve earnings quality. Investors should maintain a positive outlook given the company's ability to fund large expansions through internal accruals while maintaining cost leadership.
IOLCP Expands Portfolio with 6,000 MTPA Triacetin Plant and Pantoprazole Capacity Hike
IOL Chemicals and Pharmaceuticals (IOLCP) has announced the successful installation of a new manufacturing facility for 'Triacetin' with a capacity of 6,000 MTPA at its Barnala plant. The company also increased its Pantoprazole capacity by 15%, raising it from 240 MTPA to 276 MTPA to meet growing market demand. Both projects, involving a total capital expenditure of approximately Rs 22.75 crore, were funded entirely through internal accruals. Additionally, the board has approved the audited financial results for FY26 and scheduled the 39th AGM for September 2, 2026.
Key Highlights
New Triacetin facility established with 6,000 MTPA capacity involving Rs 16.88 crore investment
Pantoprazole capacity enhanced from 240 MTPA to 276 MTPA with an investment of Rs 5.87 crore
Both expansion projects were funded 100% through internal accruals, indicating strong cash flows
39th Annual General Meeting (AGM) fixed for 2nd September 2026 via video conferencing
Audited FY26 financial results approved with an unmodified opinion from statutory auditors
👀 What to Watch
Investors should view the diversification into Triacetin and the capacity hike in Pantoprazole as positive growth drivers that are being funded without adding debt. Monitor the utilization levels of the new Triacetin capacity in upcoming quarters to gauge its impact on the bottom line.
IOLCP Announces FY26 Results and ₹22.75 Cr Capex for Triacetin and Pantoprazole Expansion
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has successfully completed the installation of a new manufacturing facility for 'Triacetin' with a Phase-I capacity of 6,000 MTPA. The company also expanded its Pantoprazole capacity from 240 MTPA to 276 MTPA to address 100% existing capacity utilization and growing demand. The total capital expenditure of ₹22.75 crore for these projects was entirely funded through internal accruals, demonstrating strong cash flow. Additionally, the board approved the audited FY26 financial results and scheduled the 39th AGM for September 2, 2026.
Key Highlights
Launched new product 'Triacetin' with a Phase-I installed capacity of 6,000 MTPA at the Barnala plant.
Increased Pantoprazole capacity by 15%, moving from 240 MTPA to 276 MTPA to meet rising demand.
Total investment of ₹22.75 crore (₹16.88 Cr for Triacetin and ₹5.87 Cr for Pantoprazole) funded via internal accruals.
Audited FY26 financial results approved with an unmodified opinion from statutory auditors.
39th Annual General Meeting (AGM) scheduled for September 2, 2026, via video conferencing.
👀 What to Watch
Investors should view the expansion and diversification into Triacetin as a positive move for long-term revenue growth, especially as it is funded without debt. Monitor the utilization rates of the new capacities in the upcoming quarterly results to gauge market absorption.
IOLCP Promoter Group Entity NCVI Enterprises Acquires 4.04 Lakh Shares for ₹3.01 Crore
NCVI Enterprises Limited, a promoter group entity of IOL Chemicals and Pharmaceuticals Limited, has increased its stake in the company through an open market purchase. The entity acquired 4,04,305 equity shares on March 19, 2026, for a total consideration of approximately ₹3.01 crore. This transaction has resulted in the promoter group's holding rising from 16.44% to 16.58%. Such insider buying is generally perceived as a positive signal, indicating management's confidence in the company's intrinsic value and future growth.
Key Highlights
Promoter group entity NCVI Enterprises Limited purchased 4,04,305 equity shares.
The acquisition was valued at approximately ₹3.01 crore via open market transactions.
The promoter group's stake increased from 16.44% to 16.58% following the purchase.
The transaction was executed on March 19, 2026, and officially disclosed on March 20, 2026.
👀 What to Watch
Investors should take note of this promoter buying as a sign of internal confidence in the company's prospects. It serves as a positive secondary indicator for long-term holders, though it should be weighed alongside broader fundamental performance.
Promoter Group Entity Buys 6.54 Lakh Shares of IOLCP for ₹4.47 Crore
Mayadevi Polycot Limited, a promoter group entity of IOL Chemicals and Pharmaceuticals Limited, has acquired 6,54,123 equity shares through an open market transaction on March 17, 2026. The total acquisition cost was approximately ₹4.47 crore, increasing the entity's stake from 21.54% to 21.76%. This insider purchase is a positive signal, often indicating that the promoter group believes the company's shares are undervalued or has confidence in future growth.
Key Highlights
Acquisition of 6,54,123 equity shares by promoter group entity Mayadevi Polycot Limited
Total transaction value of ₹4,47,17,289 executed via on-market purchase
Promoter entity's stake increased from 21.54% to 21.76% (a 0.22% increase)
Transaction occurred on March 17, 2026, and was disclosed to exchanges on March 18, 2026
👀 What to Watch
Investors should view this promoter buying as a sign of internal confidence in the company's prospects. It may serve as a support level for the stock price, though overall market conditions and sector performance should also be considered.
IOL Chemicals Promoter Group NCVI Enterprises Acquires 7 Lakh Shares via Open Market
NCVI Enterprises Limited, a promoter group entity of IOL Chemicals and Pharmaceuticals Limited (IOLCP), has increased its stake in the company through an open market purchase. On March 16, 2026, the entity acquired 7,00,000 equity shares, representing approximately 0.24% of the company. This transaction raises the promoter group's holding from 15.96% to 16.20%. Such insider buying is generally interpreted as a positive signal of management's confidence in the company's long-term value.
Key Highlights
Promoter group entity NCVI Enterprises Limited acquired 7,00,000 equity shares on March 16, 2026.
The acquisition was executed through an open market transaction.
The promoter group's total shareholding increased from 4,68,50,695 shares (15.96%) to 4,75,50,695 shares (16.20%).
The disclosure was filed under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations.
👀 What to Watch
Promoter buying at market prices often suggests that the leadership believes the stock is undervalued or has strong growth potential. Investors should maintain a positive outlook but continue to monitor the company's quarterly earnings performance.
IOLCP Receives EDQM CEP Certificate for Metformin Hydrochloride Process-II
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Health Care (EDQM) for its API product, Metformin Hydrochloride Process-II. This certification, granted on March 5, 2026, is an addition to the company's existing valid CEP for Metformin Hydrochloride. Metformin is a widely used antidiabetic drug for managing blood sugar levels. This regulatory milestone strengthens the company's ability to supply this critical API to the European market and other regions that recognize EDQM standards.
Key Highlights
EDQM granted the CEP for Metformin Hydrochloride Process-II on March 5, 2026
The new certification is in addition to the existing valid CEP already held by the company
Metformin Hydrochloride is a key antidiabetic drug used globally for blood sugar management
The approval enhances IOLCP's regulatory compliance and market access in European territories
👀 What to Watch
Investors should view this as a positive development that reinforces IOLCP's position in the global API market. The additional certification may lead to improved operational flexibility and potential volume growth in the antidiabetic segment.
IOLCP Expands Ethyl Acetate and Acetic Anhydride Capacities via Rs 9.71 Cr Capex
IOL Chemicals and Pharmaceuticals Limited has successfully completed the expansion of its manufacturing facilities for Ethyl Acetate and Acetic Anhydride as of March 2, 2026. The Ethyl Acetate capacity has been increased by 20,000 MTPA to reach 1,20,000 MTPA, while Acetic Anhydride capacity grew by 7,000 MTPA to 32,000 MTPA. The total project cost of Rs 9.71 crore was entirely funded through internal accruals, indicating a healthy balance sheet. This expansion is strategically timed as existing facilities were operating at 90-100% utilization.
Key Highlights
Ethyl Acetate capacity increased from 1,00,000 MTPA to 1,20,000 MTPA (20% increase)
Acetic Anhydride capacity enhanced from 25,000 MTPA to 32,000 MTPA (28% increase)
Total capital expenditure of Rs 9.71 crore funded through internal accruals
Expansion completed on March 2, 2026, to address high utilization rates and market demand
Aims to improve margin realization through optimum operating leverage
👀 What to Watch
Investors should view this as a positive growth signal as the company is expanding capacity in segments where it already has high utilization. The use of internal accruals for capex further strengthens the investment case by avoiding additional debt.
IOLCP Secures EDQM CEP Certification for Clopidogrel Besilate API
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has been granted a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines & Health Care (EDQM) for its API product, Clopidogrel Besilate. This certification, issued on February 23, 2026, serves as a significant regulatory milestone for the company's cardiovascular portfolio. IOLCP already maintains a valid CEP for Clopidogrel Bisulphate, and this new addition expands its product range for the European market. The approval is expected to strengthen the company's position as a key supplier of antiplatelet medications globally.
Key Highlights
EDQM issued the CEP for Clopidogrel Besilate on February 23, 2026, following strict quality standards.
The company now holds CEPs for two variants: Clopidogrel Besilate and Clopidogrel Bisulphate.
Clopidogrel is an essential antiplatelet medication used for treating and preventing cardiovascular diseases.
This regulatory approval facilitates easier market access and compliance for IOLCP's API exports to Europe.
👀 What to Watch
This approval strengthens IOLCP's export portfolio and validates its manufacturing quality standards; investors should maintain a positive outlook on the company's API business growth.
